18F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model

18F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model

Abstract Background Quantitative imaging can facilitate patient stratification in clinical trials. The hypoxia-activated prodrug evofosfamide recently failed a phase III trial in pancreatic cancer. However, the study did not attempt to select for patients with hypoxic tumors. We tested the ability o...

Full description

Bibliographic Details
Main Authors: Milan Grkovski, Louise Fanchon, Naga Vara Kishore Pillarsetty, James Russell, John L. Humm
Format: Article
Language:English
Published: SpringerOpen 2018-06-01
Series:EJNMMI Research
Subjects:
Evofosfamide
18F-fluoromisonidazole
Hypoxia
Pancreatic cancer
Personalized medicine
Online Access:http://link.springer.com/article/10.1186/s13550-018-0409-1

Internet

http://link.springer.com/article/10.1186/s13550-018-0409-1

Similar Items